Patents by Inventor Julie F. Liu
Julie F. Liu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 8993570Abstract: This invention relates to novel substituted triazolo-pyridazines and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an ?1-GABAA receptor antagonist or an ?2- and/or an ?3-GABAA receptor partial agonist.Type: GrantFiled: August 5, 2013Date of Patent: March 31, 2015Assignee: Concert Pharmaceuticals, Inc.Inventors: Scott L. Harbeson, Roger Tung, Julie F. Liu
-
Patent number: 8987442Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.Type: GrantFiled: April 17, 2012Date of Patent: March 24, 2015Assignee: Concert Pharmaceuticals, Inc.Inventors: Roger D. Tung, Julie F. Liu, Scott L. Harbeson
-
Patent number: 8952016Abstract: This invention relates to novel compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. For example, this invention relates to novel substituted xanthine derivatives that are derivatives of pentoxifylline. The compound of the invention are represented by one of the following structural formulas: The variables for these structural formulas are described herein. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial.Type: GrantFiled: September 1, 2010Date of Patent: February 10, 2015Assignee: Concert Pharmaceuticals, Inc.Inventors: Roger D. Tung, Julie F. Liu, Scott L. Harbeson
-
Patent number: 8889687Abstract: This invention in one embodiment is directed to a compound of Formula Ia; where the designation (R) indicates that the designated carbon has the (R) stereochemistry; and wherein Z1 is hydrogen or fluorine; Z2 is hydrogen, deuterium, or fluorine; Z3 is deuterium; Z4 is fluorine; m is an integer from 0 to 10; n is an integer from 0 to 2; provided that: the sum of m+n does not exceed 10; and when both Z1 and Z2 are hydrogen, the sum of m+n is greater than 0, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an antihelminthic agent, such as praziquantel.Type: GrantFiled: March 2, 2012Date of Patent: November 18, 2014Assignee: Concert Pharmaceuticals, Inc.Inventors: Julie F. Liu, Roger Tung, Scott L. Harbeson
-
Patent number: 8883843Abstract: This invention relates to novel substituted isoindoline-1,3-dione derivatives and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel substituted isoindoline-1,3-dione derivatives that are analogs of apremilast. This invention also provides compositions comprising a compound of this invention and a carrier and the use of disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering apremilast.Type: GrantFiled: December 20, 2012Date of Patent: November 11, 2014Assignee: Concert Pharmaceuticals, Inc.Inventor: Julie F. Liu
-
Patent number: 8765723Abstract: This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administration of a phosphodiesterase inhibitor, such as cilostazol. The invention also relates to the use of the disclosed compounds and compositions as reagents in analytical studies involving cilostazol.Type: GrantFiled: January 7, 2013Date of Patent: July 1, 2014Assignee: CoNCERT Pharmaceuticals, Inc.Inventors: Rose A. Persichetti, Julie F. Liu, Craig E. Masse, Scott L. Harbeson
-
Publication number: 20140121226Abstract: This invention relates to novel deuterated compounds that are substituted xanthine derivatives and pharmaceutically acceptable salts thereof. In particular, this invention relates to novel substituted xanthine derivatives that are deuterated derivatives of a pentoxifylline metabolite. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed deuterated compounds and compositions in methods of treating diseases and conditions for which pentoxifylline and related compounds are beneficial. The compounds of the invention are represented by the following structural formula: wherein the values of R1, R2, R3, R4, R5, Y1 and Y2 are described herein.Type: ApplicationFiled: July 24, 2013Publication date: May 1, 2014Applicant: CONCERT PHARMACEUTICALS, INC.Inventors: Roger D. Tung, Julie F. Liu, Scott L. Harbeson
-
Publication number: 20140107127Abstract: This invention relates to novel compounds that are pyrazinoisoquinoline derivatives, and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel pyrazinoisoquinoline derivatives that are derivatives of praziquantel. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by ad ministering an antihelminthic agent, such as praziquantel.Type: ApplicationFiled: September 18, 2013Publication date: April 17, 2014Inventors: Julie F. Liu, Scott L. Harbeson, Roger D. Tung
-
Publication number: 20130317033Abstract: This invention relates to novel substituted triazolo-pyridazines and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an ?1-GABAA receptor antagonist or an ?2- and/or an ?3-GABAA receptor partial agonist.Type: ApplicationFiled: August 5, 2013Publication date: November 28, 2013Applicant: CONCERT PHARMACEUTICALS, INC.Inventors: Scott L. Harbeson, Roger Tung, Julie F. Liu
-
Publication number: 20130281456Abstract: The present invention is directed to a process for preparing a 2,26,6-d4-morpholine derivative represented by Structural Formula (I): or a salt thereof.Type: ApplicationFiled: November 15, 2012Publication date: October 24, 2013Inventors: Julie F. Liu, Xuejun Tang, Scott L. Harbeson, Craig E. Masse
-
Patent number: 8563554Abstract: This invention relates to novel compounds that are pyrazinoisoquinoline derivatives, and pharmaceutically acceptable salts thereof. More specifically, this invention relates to novel pyrazinoisoquinoline derivatives that are derivatives of praziquantel, such as compounds of formula (I): or pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an antihelminthic agent, such as praziquantel.Type: GrantFiled: March 16, 2010Date of Patent: October 22, 2013Assignee: Concert Pharmaceuticals, Inc.Inventors: Julie F. Liu, Scott L. Harbeson, Roger Tung
-
Patent number: 8501738Abstract: This invention relates to novel substituted triazolo-pyridazines and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an ?1-GABAA receptor antagonist or an ?2- and/or an ?3-GABAA receptor partial agonist.Type: GrantFiled: June 22, 2010Date of Patent: August 6, 2013Assignee: Concert Pharmaceuticals, Inc.Inventors: Scott L. Harbeson, Julie F. Liu
-
Publication number: 20130121963Abstract: This disclosure relates to novel N-phenyl-2-pyrimidineamines and pharmaceutically acceptable salts thereof. This disclosure also provides compositions comprising a compound of this disclosure and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering protein-tyrosine kinase inhibitors.Type: ApplicationFiled: May 16, 2012Publication date: May 16, 2013Applicant: Concert Pharmaceuticals Inc.Inventors: Scott L. Harbeson, Julie F. Liu, Roger Tung
-
Publication number: 20130109707Abstract: This invention relates to novel fluorouracil derivatives of Formula I or pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a thymidylate synthase inhibitor.Type: ApplicationFiled: February 28, 2011Publication date: May 2, 2013Applicant: Concert Pharmaceuticals ,Inc.Inventors: Rose A. Persichetti, Julie F. Liu
-
Patent number: 8410082Abstract: This invention relates to novel diaryl urea compounds, their derivatives, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an inhibitor of multiple kinases.Type: GrantFiled: May 20, 2010Date of Patent: April 2, 2013Assignee: Concert Pharmaceuticals, Inc.Inventors: Julie F. Liu, Roger D. Tung, Scott L. Harbeson
-
Patent number: 8404737Abstract: This invention relates to novel substituted isoindoline-1,3-dione derivatives and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel substituted isoindoline-1,3-dione derivatives that are analogues of apremilast. This invention also provides compositions comprising a compound of this invention and a carrier and the use of disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering apremilast.Type: GrantFiled: February 2, 2012Date of Patent: March 26, 2013Assignee: Concert Pharmaceuticals, Inc.Inventor: Julie F. Liu
-
Patent number: 8367674Abstract: This invention relates to novel compounds that are piperazine derivatives, and pharmaceutically acceptable salts thereof. More specifically, the invention relates to novel piperazine compounds that are derivatives of the chemokine CCR5 receptor antagonist, vicriviroc. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administering chemokine CCR5 receptor antagonists, such as vicriviroc. The invention also relates to the use of one or more of the disclosed compounds as reagents in analytical studies involving vicriviroc.Type: GrantFiled: April 17, 2009Date of Patent: February 5, 2013Assignee: CoNCERT Pharmaceuticals, Inc.Inventors: Julie F. Liu, Rose Persichetti
-
Publication number: 20130029997Abstract: This invention in one embodiment is directed to a compound of Formula Ia; where the designation (R) indicates that the designated carbon has the (R) stereochemistry; and wherein Z1 is hydrogen or fluorine; Z2 is hydrogen, deuterium, or fluorine; Z3 is deuterium; Z4 is fluorine; m is an integer from 0 to 10; n is an integer from 0 to 2; provided that: the sum of m+n does not exceed 10; and when both Z1 and Z2 are hydrogen, the sum of m+n is greater than 0, and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising one or more compounds of this invention and a carrier and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are beneficially treated by administering an antihelminthic agent, such as praziquantel.Type: ApplicationFiled: March 2, 2012Publication date: January 31, 2013Applicant: Concert Pharmaceuticals, Inc.Inventors: Julie F. Liu, Roger Tung, Scott L. Harbeson
-
Patent number: 8357674Abstract: This invention relates to novel compounds which are derivatives of the phosphodiesterase inhibitor, cilostazol and pharmaceutically acceptable salts thereof. This invention also provides pyrogen-free compositions comprising one or more compounds of the invention and the use of the disclosed compounds and compositions in methods of treating diseases and conditions that are treated by administration of an phosphodiesterase inhibitor, such as cilostazol. The invention also relates to the use of the disclosed compounds and compositions as reagents in analytical studies involving cilostazol.Type: GrantFiled: June 29, 2012Date of Patent: January 22, 2013Assignee: CoNCERT Pharmaceuticals, Inc.Inventors: Julie F. Liu, Rose A. Persichetti
-
Publication number: 20130018193Abstract: This invention relates to novel substituted pyridinones, their derivatives, pharmaceutically acceptable salts, solvates, and hydrates thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a TNF (tumor necrosis factor)-alpha production inhibitor/TGF (transforming growth factor)-beta inhibitor.Type: ApplicationFiled: March 27, 2012Publication date: January 17, 2013Inventors: Julie F. Liu, Yong Dong